Similarly, VEGF-A rs3025039T positive genotypes are significantly increased with respect to the controls both in BCC (recessive model OR 3.94, CI 95% 1.15–13.49, p < 0.0001) and SCC patients (dominant model OR 2.86, CI 95% 1.09–7.50, p = 0.034). This evidence concerns the gene VEGFA and skin basal cell carcinoma.